文献速递慢性肾脏病水电解质与酸碱

成纤维细胞生长因子23、尿磷酸盐与CKD进展风险

Fibroblast Growth Factor 23, Urinary Phosphate, and Risk of Progression of CKD.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-11-06

这项在日本三级医疗中心开展的观察性研究纳入946例非透析依赖的CKD患者,采用自动化学发光酶免疫分析法测定完整FGF23水平。中位随访27.2个月,181例发生复合肾脏结局;最高四分位组相比最低四分位组的风险比为2.12(95%CI 1.05–4.28),且低24小时尿磷酸盐排泄患者中关联更明显。

要点

  • 高iFGF23水平与CKD复合肾脏结局风险升高相关。
  • 低24小时尿磷酸盐排泄患者中该关联更明显。
  • iFGF23联合24小时尿磷酸盐排泄或有助于预测CKD进展。

核心结论

  • 高iFGF23水平与非透析依赖CKD患者的复合肾脏结局相关。
  • 该关联在低24小时尿磷酸盐排泄患者中更明显。

研究设计与样本

  • 观察性研究,纳入日本一家三级医疗中心的946例非透析依赖CKD患者。
  • 采用自动化学发光酶免疫分析法测定iFGF23水平。
  • 使用Cox回归分析iFGF23与复合肾脏结局的关联,并用限制性立方样条分析非线性关系。

主要发现

  • 中位eGFR为46 ml/min per 1.73 m2,中位随访27.2个月,181例发生复合肾脏结局。
  • 多变量Cox回归显示,最高四分位组(Q4)相比参照组Q1的复合肾脏结局风险比为2.12(95%CI 1.05–4.28)。
  • 限制性立方样条分析结果一致。
  • 高FGF23水平与复合肾脏结局的关联在低24小时尿磷酸盐排泄患者中更明显。
  • 磷酸盐分数排泄未改变该关联。

关键数值与推荐

  • 复合肾脏结局定义为肾脏衰竭并接受替代治疗或eGFR下降40%。
  • iFGF23最高四分位组相比最低四分位组的风险比为2.12(95%CI 1.05–4.28)。

临床怎么用

  • 在非透析依赖CKD患者中,可关注iFGF23水平以辅助风险评估。
  • 结合24小时尿磷酸盐排泄可能有助于识别进展风险更高的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: High intact fibroblast growth hormone 23 levels, measured by automated chemiluminescent enzyme immunoassay, were associated with composite kidney outcomes in non–dialysis-dependent CKD. The association between intact fibroblast growth hormone 23 levels and outcomes was more pronounced in patients with low 24-hour urinary phosphate excretion. Fibroblast growth hormone 23 with 24-hour urinary phosphate excretion may assist in predicting the progression of CKD. BACKGROUND: Association between fibroblast growth hormone 23 (FGF23) levels and kidney outcomes and the effect of urinary phosphate excretion (UPE) on this association remain uncertain. This study aimed to investigate the association between FGF23 levels and kidney outcomes on the basis of UPE levels. METHODS: This observational study included 946 patients with non–dialysis-dependent CKD at a tertiary medical center in Japan. Intact FGF23 (iFGF23) levels were measured using an automated chemiluminescent enzyme immunoassay. The association between iFGF23 levels and composite kidney failure with replacement therapy and a 40% decline in eGFR was investigated using Cox regression analysis. A nonlinear relationship was investigated using restricted cubic spline analysis. Subgroup analyses on the basis of 24-hour UPE and fractional excretion of phosphate were also performed. RESULTS: The median eGFR level was 46 ml/min per 1.73 m2. During a median follow-up period of 27.2 months, 181 patients experienced composite kidney outcomes. Multivariable Cox regression analysis showed that the risk of composite kidney outcomes was higher in the highest FGF23 category of quartile 4 compared with that in a reference category of quartile 1, with a hazard ratio of 2.12 (95% confidence interval: 1.05 to 4.28). Restricted cubic spline analysis yielded consistent results. The association between high FGF23 levels and composite kidney outcomes was more pronounced in patients with low 24-hour UPE levels. However, fractional excretion of phosphate did not modify this association. CONCLUSIONS: High iFGF23 levels are associated with composite kidney outcomes in patients with non–dialysis-dependent CKD. This association was more pronounced in those with low 24-hour UPE levels.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Kosugi T, Eriguchi M, Tamaki H, et al. Fibroblast Growth Factor 23, Urinary Phosphate, and Risk of Progression of CKD. Clin J Am Soc Nephrol. 2025. PMID: 41196649. doi:10.2215/CJN.0000000870

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。